Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib in Platinum-ineligible Urothelial Carcinoma
NCT03837821Phase 1Active, not recruiting
- Sponsor
- Weill Cornell Medicine
- Start
- Feb 2019
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of abemaciclib in urothelial carcinoma (UC), sponsored by Weill Cornell Medicine. Primary endpoint: Change in cell-cycle dynamics between pre- and post-Abemaciclib tumor samples at 4 weeks. Started Feb 2019; status: active, not recruiting.
02
Drugs
abemaciclib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03837821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03837821.